IP Library › Granted Patent US 10,017,573
Granted Patent B2
US 10,017,573 · App. 14/241,099 · Granted Jul 10, 2018

Anti-αβTCR antibody

Inventors: Daniel Snell (Thalwil, CH); Andreas Menrad (Ely, GB); Gina Lacorcia (Concord, MA); Srinivas Shankara (Shrewsbury, MA); Huawei Qiu (Westborough, MA); Clark Pan (Sudbury, MA); Benjamin Kebble (Zurich, CH)
Assignee: GENZYME CORPORATION
C07K16/2809C07K16/2893C07K2317/24C07K2317/31C07K2317/71C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,017,573
App. No.
14/241,099
Granted
Jul 10, 2018
Kind
B2
Abstract

The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.

Claims (12)

1. A humanized monoclonal antibody specific for the human αβTCR/CD3 complex which comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 12, 13, 15 and 16, a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO 14, and a constant region of human origin, wherein the constant region comprises an Fc modification with a modified glycosylation pattern that reduces Fcγ receptor binding, wherein the Fc modification is selected from the group consisting of N297Q/S298N/Y300S, S298N/T299A/Y300S, and S298N/Y300S.

2. The humanized monoclonal antibody of claim 1 , wherein the heavy chain variable region amino acid sequence is selected from the group consisting of the amino acid sequences set forth as SEQ ID NO: 7, SEQ ID NO: 12 and SEQ ID NO: 13.

3. The humanized monoclonal antibody of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 15 and SEQ ID NO: 16.

4. The humanized antibody of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 16.

5. The humanized antibody of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 15.

6. The humanized antibody of claim 1 , wherein the Fcγ receptor is one or more receptor selected from the group consisting of FcγRIIIa and FcγRI.

7. A pharmaceutical composition, comprising the antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.

8. A pharmaceutical composition, comprising the antibody of claim 4 and a pharmaceutically acceptable carrier or diluent.

9. A pharmaceutical composition, comprising the antibody of claim 5 and a pharmaceutically acceptable carrier or diluent.

10. The humanized monoclonal antibody of claim 1 , wherein the Fc modification is N297Q/S298N/Y300S.

11. The humanized monoclonal antibody of claim 1 , wherein the Fc modification is S298N/T299A/Y300S.

12. The humanized monoclonal antibody of claim 1 , wherein the Fc modification is S298N/Y300S.

Continuity (2)
Provisional Application 61533510 · Sep 12, 2011
Related Publication 20150099861A1 · Apr 9, 2015
Cited By (4)
US 12,365,734 US 12,503,498 US 12,612,458 US 12,674,003